120 related articles for article (PubMed ID: 27608899)
1. Identifying the role of PTPN12 expression in predicting the efficacy of capecitabine to neoadjuvant chemotherapy in breast cancer treatment.
Wang YY; Liu H; Mao XY; Jin F; Ma B; Jiang JY; Cao Y
Eur Rev Med Pharmacol Sci; 2016 Aug; 20(16):3400-9. PubMed ID: 27608899
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of PTPN12 expression in human breast cancer.
Xunyi Y; Zhentao Y; Dandan J; Funian L
Braz J Med Biol Res; 2012 Dec; 45(12):1334-40. PubMed ID: 23044628
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Cao X; Li Y; Luo RZ; He LR; Yang J; Zeng MS; Wen ZS
Ann Thorac Surg; 2012 May; 93(5):1674-80. PubMed ID: 22429674
[TBL] [Abstract][Full Text] [Related]
4. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.
Sun T; Aceto N; Meerbrey KL; Kessler JD; Zhou C; Migliaccio I; Nguyen DX; Pavlova NN; Botero M; Huang J; Bernardi RJ; Schmitt E; Hu G; Li MZ; Dephoure N; Gygi SP; Rao M; Creighton CJ; Hilsenbeck SG; Shaw CA; Muzny D; Gibbs RA; Wheeler DA; Osborne CK; Schiff R; Bentires-Alj M; Elledge SJ; Westbrook TF
Cell; 2011 Mar; 144(5):703-18. PubMed ID: 21376233
[TBL] [Abstract][Full Text] [Related]
5. Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Li J; Davidson D; Martins Souza C; Zhong MC; Wu N; Park M; Muller WJ; Veillette A
Mol Cell Biol; 2015 Dec; 35(23):4069-82. PubMed ID: 26391955
[TBL] [Abstract][Full Text] [Related]
6. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS
Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer.
Thummuri D; Kumar S; Surapaneni SK; Tikoo K
Life Sci; 2015 Jun; 130():73-80. PubMed ID: 25817229
[TBL] [Abstract][Full Text] [Related]
9. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
11. DJ-1 protein expression as a predictor of pathological complete remission after neoadjuvant chemotherapy in breast cancer patients.
Kawate T; Iwaya K; Kikuchi R; Kaise H; Oda M; Sato E; Hiroi S; Matsubara O; Kohno N
Breast Cancer Res Treat; 2013 May; 139(1):51-9. PubMed ID: 23592371
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
Dai XL; Han ZB; Yang YT; Qiu J; Liu YF; Feng YZ
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):517-22. PubMed ID: 25907177
[TBL] [Abstract][Full Text] [Related]
14. [Value of FOXP3 Tregs predicting the effectiveness of neoadjuvant chemotherapy in patients with breast cancer].
Su J; Chen H; Li M; Dong J; Lin Z
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(8):595-7. PubMed ID: 25917035
[TBL] [Abstract][Full Text] [Related]
15. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Huober J; von Minckwitz G; Denkert C; Tesch H; Weiss E; Zahm DM; Belau A; Khandan F; Hauschild M; Thomssen C; Högel B; Darb-Esfahani S; Mehta K; Loibl S
Breast Cancer Res Treat; 2010 Nov; 124(1):133-40. PubMed ID: 20697801
[TBL] [Abstract][Full Text] [Related]
16. [Effect of single nucleotide polymorphisms of RS1799937 located in WT1 gene on the pathlogical complete response to neoadjuvant chemotherapy in breast cancer patients].
Li MM; Shao YB; Liu H; Xu B; He BX
Zhonghua Yi Xue Za Zhi; 2016 Nov; 96(44):3559-3562. PubMed ID: 27916075
[No Abstract] [Full Text] [Related]
17. A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
Jin X; Jiang YZ; Chen S; Yu KD; Ma D; Sun W; Shao ZM; Di GH
BMC Cancer; 2016 Aug; 16():606. PubMed ID: 27495967
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Zambetti M; Mansutti M; Gomez P; Lluch A; Dittrich C; Zamagni C; Ciruelos E; Pavesi L; Semiglazov V; De Benedictis E; Gaion F; Bari M; Morandi P; Valagussa P; Luca G
Breast Cancer Res Treat; 2012 Apr; 132(3):843-51. PubMed ID: 21750964
[TBL] [Abstract][Full Text] [Related]
19. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
Harris IS; Blaser H; Moreno J; Treloar AE; Gorrini C; Sasaki M; Mason JM; Knobbe CB; Rufini A; Hallé M; Elia AJ; Wakeham A; Tremblay ML; Melino G; Done S; Mak TW
Oncogene; 2014 Feb; 33(8):1047-54. PubMed ID: 23435421
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
